In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.

A new pilot program from the federal government has hospital and pharmacy leaders bracing for what they describe as a fundamental dismantling of the ...

Clearway Health, a specialty pharmacy services company, announced several initiatives today aimed at helping hospitals and ...

The Kansas Legislature is currently considering a bill, SB 284, under seemingly noble pretense. Proponents of SB 284 argue ...

AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.

If HHS' 340B rebate model pilot proceeds as planned, more than 2,700 U.S. hospitals will collectively be saddled with approximately $400 million ...

Investments in Uncompensated Care and Vulnerable Populations Have Decreased on Average While Hospital Investments in Financial Portfolios Have Ballooned A new analysis of 340B hospital data found that ...

Cambridge Health Alliance is “deeply concerned” about proposed changes to a prescription drug discount program that has ...

The American Hospital Association and America's Essential Hospitals have joined five other 340B stakeholders in a lawsuit against the Department of Health and Human Services over its delay in ...

Ryan Long, the co-author of a recent USC Schaeffer Center white paper on the 340B Drug Pricing Program, argues that meaningful reform requires shifting to a direct subsidy model based on need.

Drug companies are more likely than hospitals to violate 340B regulations, according to a recent American Hospital Association report. The 340B Drug Pricing Program has been under constant attack on ...

The vast majority of hospitals that participate in the 340B drug pricing program do not follow recent hospital transparency regulations requiring them to report the prices they charge for oncology ...